中新健康｜政策搭台平台铺路 中国创新药械加速“出海”

Core Insights - The article discusses China's strategy to promote its pharmaceutical products globally, focusing on the role of the National Medical Insurance Administration (NMI) in enhancing the internationalization of the Chinese pharmaceutical industry [1][2]. Group 1: Policy and Framework - The NMI has identified the establishment of an innovative international procurement model for medical supplies as a key focus for 2026, leveraging regional advantages of various procurement platforms [1]. - A systematic policy support framework is being developed through collaboration among multiple departments, including the Ministry of Commerce and the Ministry of Industry and Information Technology, to facilitate the international expansion of pharmaceutical products [2][4]. Group 2: Pricing and Registration Systems - The China Drug Price Registration System was launched in December 2025 to create a transparent pricing mechanism for Chinese pharmaceuticals in international markets, with the first overseas drug price certificate issued in January 2026 [3]. - As of January 16, 2026, the registration system has received applications from 60 companies, covering 22 drugs across various categories, indicating a growing interest in international pricing standards [3]. Group 3: Regional Trade Platforms - Regional trade platforms are being established in areas like Guangxi and Xinjiang to enhance the supply of Chinese pharmaceuticals to Southeast Asia and Central Asia, with the China-ASEAN regional pharmaceutical trading platform already operational [4]. - The China-Central Asia "Central Pharmacy" is set to launch in 2026, aiming to integrate services and improve market penetration in Central Asia [4]. Group 4: Industry Insights and Strategies - Companies like Yifan Pharmaceutical emphasize that international expansion is essential for survival and growth, highlighting the need for differentiated innovative products and strong international partnerships [5][6]. - The industry is witnessing a shift from being a "generic drug production powerhouse" to becoming a "leading exporter of innovative drugs," with significant increases in approved innovative drugs and medical devices [6].